中
中文
日本語

Our Mission
Inclusive and Open to Diversity,
Innovationoriented to Win Together
and Benefit the Mankind

Haihe Mission

Our Mission and Purpose

About Us
Learn More

  • Established in

    2011

  • Headquartered in

    Pudong

    Shanghai

    China

  • China

    Indigenous

    Innovative

    Biopharma

    Company

  • Specializing in the Discovery,

    Development, Production

    and Commercialization

    Innovative Oncology

    Drugs

  • Academician1

    Scientists100

    Doctorate
    Degree    25

    Number of
    Employees    134

    Master’s
    Degree    37


    As of DEC.31,2025

  • Core Products

    in R&D Pipeline

    10+

 
R&D Field
Strong, Innovation-driven R&D Capabilities
Learn More
  • Have obtained multiple proprietary global intellectual property rights
  • Multiple global clinical research projects are ongoing simultaneously
  • Have been recognized by authoritative industry institutions
Cancer Types Covered by the R&D Pipeline
Rich and Balanced Pipeline
  • 1 product – Gumarontinib, an oral highly selective mesenchymal-epithelial transition (MET) inhibitor and a Category 1 innovative new chemical drug has been conditionally approved by NMPA that Haihe owns its global intellectual property rights.
  • 10+ Oncology+Non-oncology compounds in core pipeline, including those in late clinical stage and pre-clinical stage
  • Multiple potential best-in-class compounds are expected to be used in monotherapy or combination to treat major indications
Explore
Company Milestones

Haihe Biopharma is an innovation-driven biotechnology company in China focusing on the discovery, development, production and commercialization of innovative anti-tumor drugs. Haihe brings life-saving therapies to cancer patients worldwide. 

Our Stories
  •  

    March 2023

    Haihe Biopharma’s Gumarontinib has been approved by NMPA

  •  

    March 2022

     NMPA-CDE Grants Priority Review Designation to Haihe Biopharma's Gumarontinib

  •  

    February 2022

    The NDA for Haihe Biopharma’s Gumarontinib has been accepted for review by the CDE.

  •  

    March 2021

    Haihe established its Japan office

  •  

    July 2020

    Haihe completed the reorganization of related group companies. Shanghai Haihe Pharmaceutical Research and Development Co Ltd acquired the stakes of Shanghai RMX Biopharma Co Ltd.

  •  

    December 2019

    Haihe established its US office

  •  

    October 2019

    Haihe’s Manufacturing Hub set foot in Taizhou China Medical City, with planned investment of 600 million yuan

  •  

    April 2019

    Haihe completed the first patient dosing of oral paclitaxel RMX3001 phase III clinical trial for advanced gastric cancer

  •  

    September 2018

    Haihe reached strategic cooperation agreements with Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Tigermed, Junshi Biosciences, 3D Medicines, and Jiuzhou Pharmaceutical

  •  

    March 2018

    Haihe Pharmaceutical merged with Nuomaixi Pharmaceutical to form Haihe Biopharma Co, Ltd.

News Center
Read More
Haihe Biopharma's innovative drug PARP1 inhibitor has obtained clinical trial approval in China
2025.11.07
Haihe Biopharma Enters Into Exclusive License Agreement with Taiho Pharma for PI3Kα Inhibitor Risovalisib (CYH33)
2025.10.16
HaiHe Biopharma's Selective PI3Kα Inhibitor was Granted Orphan Drug Designation in Japan
2025.06.30
Haihe Biopharma Presented results of two clinical studies in 2024 CSCO Annual Meeting
2024.09.28
Haihe Biopharma Announces that Paclitaxel Oral Solution (RMX3001) was Approved by NMPA as Second-line Treatment for Gastric Cancer
2024.09.25
Haihe Biopharma and Taiho Pharmaceutical Announce the Launch of MET Inhibitor HAIYITAN® Tablets 50mg in Japan
2024.09.24
An innovative drug Gumarontinib (MET inhibitor) discovered and developed by Haihe Biopharma has been successfully approved in Japan
2024.06.24
Haihe Biopharma Presented results of two clinical studies in 2024 ASCO Annual Meeting
2024.06.03
Haihe Biopharma are presenting two drug discovery projects in 2024 AACR Annual Meeting
2024.04.07
Haihe Biopharma Enters Exclusive License Agreement with Taiho Pharma for Gumarontinib (SCC244), an Agent for Non-Small Cell Lung Cancer
2024.03.01
Join Us
Let’s ride the wave of developing original innovative drugs in China. Haihe Biopharma aspires to become one of the companies that R&D professionals and outstanding managers have the strongest desire to join.
Job Opportunities
| Legal statement | Disclaimers | Contact |
Follow Us
© 2020 All Rights Reserved Haihe Biopharma Co., Ltd.
沪ICP备12016151号-1